Subscribe
scotus-istock-482156434-1
renaschild / iStockphoto.com
20 March 2019Big Pharma

Allergan and tribe hit back at Mylan claims in SCOTUS brief

Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
English High Court invalidates Allergan glaucoma patent
7 May 2019   One of Allergan’s patents has been invalidated after it was challenged by UK-based pharmaceutical companies Accord Healthcare and Aspire Pharma.
Americas
SCOTUS refuses to hear tribal immunity suit
16 April 2019   The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Americas
Allergan and tribe ask for stay pending SCOTUS appeal
29 October 2018   Allergan and the Saint Regis Mohawk Tribe have urged the US Court of Appeals for the Federal Circuit to stay its ruling against them pending an appeal to the US Supreme Court.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
English High Court invalidates Allergan glaucoma patent
7 May 2019   One of Allergan’s patents has been invalidated after it was challenged by UK-based pharmaceutical companies Accord Healthcare and Aspire Pharma.
Americas
SCOTUS refuses to hear tribal immunity suit
16 April 2019   The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Americas
Allergan and tribe ask for stay pending SCOTUS appeal
29 October 2018   Allergan and the Saint Regis Mohawk Tribe have urged the US Court of Appeals for the Federal Circuit to stay its ruling against them pending an appeal to the US Supreme Court.

More on this story

Big Pharma
English High Court invalidates Allergan glaucoma patent
7 May 2019   One of Allergan’s patents has been invalidated after it was challenged by UK-based pharmaceutical companies Accord Healthcare and Aspire Pharma.
Americas
SCOTUS refuses to hear tribal immunity suit
16 April 2019   The US Supreme Court has declined to hear a closely-watched case on tribal immunity involving pharmaceutical company Allergan and the Saint Regis Mohawk Tribe, a Native American tribe.
Americas
Allergan and tribe ask for stay pending SCOTUS appeal
29 October 2018   Allergan and the Saint Regis Mohawk Tribe have urged the US Court of Appeals for the Federal Circuit to stay its ruling against them pending an appeal to the US Supreme Court.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims